Evidence map›Paper›PMID 33322999›Full record

ArticleThe Journal of international medical research2020

Haemorrhagic cystitis following the administration of voriconazole in the treatment of central nervous system aspergillosis: a case report.

Zhaohao Zeng, Hong Luo, Kunyu Huang, Lianfang Xue, Hui Liu, Xiaoting Li, Lu Wang, Haimei Cen, Wei Bi, Yu Zhang

Open access · goldAbstract readCase Reports
In one paragraph

Article in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhaohao ZengDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Hong LuoDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Kunyu HuangDepartment of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Lianfang XueDepartment of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Hui LiuDepartment of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Xiaoting LiDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Lu WangDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Haimei CenDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
Wei BiDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.ORCID https://orcid.org/0000-0003-2371-2791
Yu ZhangDepartment of Neurology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong Province, China.
First Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system aspergillosis (CNS-A) is a rare and fatal fungal infection. Voriconazole is the recommended treatment for CNS-A. The therapeutic effect of voriconazole is good, but its use is limited due to adverse reactions. This case report describes a 37-year-old male patient that had previously been diagnosed with acute lymphoblastic leukaemia. He had received immunosuppressive agents for 1 year following a haematopoietic bone marrow transplant. He presented with a 1-month history of left limb weakness as well as recurrent fever. Brain magnetic resonance imaging showed that he had multiple cerebral infarctions. Subsequently, he was diagnosed with CNS-A by metagenomic next-generation sequencing. Voriconazole was added to his treatment regimen, but it resulted in severe haemorrhagic cystitis and possibly bladder rupture. The dose of voriconazole was adjusted and reparative bladder surgery was undertaken immediately. Eventually, the patient was successfully treated with voriconazole and there was no recurrence of symptoms after 1 year of follow-up. Haemorrhagic cystitis is a rare adverse drug reaction associated with voriconazole use. Based on the experience with this current case, physicians should be aware of urinary tract complications with voriconazole including haemorrhagic cystitis.

Indexed as

AspergillosisCystitisAdultAntifungal AgentsHumansMaleNeoplasm Recurrence, LocalVoriconazoleAntifungal AgentsVoriconazoleadverse drug reactionCentral nervous system aspergillosis (CNS-A)cerebral infarctionvoriconazole

Identifiers

PMID33322999
PMCPMC7745564
OpenAlexW3111413890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.